Exit
Before you view this Expert Consult video, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. Which of the following therapies has demonstrated the longest median progression-free survival in phase 1 studies of patients with relapsed/refractory multiple myeloma?

Question Title

* 4. Enrollment of patients with which of the following characteristics is a key difference in the study populations presented in the MonumenTAL-1 (talquetamab) study compared with the MagnetisMM-3, MajesTEC-1, KarMMa-1 or CARTITUDE-1 studies? 

Question Title

* 5. An organizational task force is developing monitoring plans for patients receiving bispecific antibodies for relapsed/refractory multiple myeloma. Monitoring for which of the following adverse effects should be included in monitoring plans for talquetamab but not for elranatamab or teclistamab? 

Question Title

* 6. A 68-year-old male was referred for management of relapsed/refractory multiple myeloma after 7 prior therapies including 2 proteasome inhibitors, 2 immunomodulatory agents, and 2 anti-CD38 monoclonal antibodies. After reviewing treatment options with him, he asks which of the following severe (grade 3 or higher) adverse effects is more likely to occur if he chooses a BCMA-directed bispecific antibody rather than a BCMA-directed CAR-T? Which of the following is the best response? 

Question Title

* 7. A 63-year-old female diagnosed with IgG multiple myeloma with deletion 17p presents for a treatment consult. She received 5 prior therapies including 2 proteasome inhibitors, 2 immunomodulatory agents, and 2 anti-CD38 monoclonal antibodies. She is the caregiver for her spouse with advanced Alzheimer’s disease. They live 200 miles from a cellular therapy center. She wishes to receive treatment close to home. Which therapy is best for her at this time? 

Question Title

* 8. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity) 

Completing the fields below does not immediately qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

*Please note that we will not forward or sell your contact information.

( Privacy & Cookie Notice

T